<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017585</url>
  </required_header>
  <id_info>
    <org_study_id>Policlinic Hospital 5, Bari</org_study_id>
    <nct_id>NCT04017585</nct_id>
  </id_info>
  <brief_title>Identification of Gluten Sensitivity in Irritable Bowel Syndrome</brief_title>
  <acronym>IBS-NCGS</acronym>
  <official_title>Double Blind Randomized Clinical Trial in Subjects With Irritable Bowel Syndrome for the Identification of Gluten Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study will be to establish in how many subjects with gastrointestinal symptoms
      and previous diagnosis of irritable bowel syndrome (IBS), the clinical picture is
      attributable to non celiac gluten sensitivity (NCGS) or fermentable oligosaccharides,
      disaccharides, monosaccharides and polyols (FODMAPs) intolerance. For this purpose, all
      subjects with IBS will take a low FODMAPs diet, which implies the absence of cereals and
      consequently of gluten, and those presenting symptom improvement during this dietary
      treatment, will be exposed to a double-blind gluten or placebo challenge, to make a diagnosis
      of NCGS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      For this study, patients with diagnosis of IBS performed by Rome IV criteria and followed as
      outpatients at the Clinical Nutrition Clinic of &quot;Petrucciani&quot; Nursing Home of Lecce (LE),
      Italy, will be enrolled.

      At baseline, the enrolled subjects will follow a balanced normal-caloric low-FODMAP and
      gluten-free diet for a period of 4 weeks. At the end of the 4 weeks patients who did not
      experience an improvement in symptoms will be considered &quot;non-responders&quot; and discontinue the
      clinical trial. Only those subjects who had showed a significant improvement in symptoms,
      will be enrolled for the phase 2 of the study that includes a challenge with gluten or with
      placebo, as described by the Salerno criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of FODMAP intollerance in IBS subjects</measure>
    <time_frame>4 weeks</time_frame>
    <description>To evaluate the FODMAP intolerance, the response to a low FODMAP diet will be assessed by a visual analogue scale (VAS) before and after the dietary challenge. The VAS scale consists in is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptoms, pain, subjective feeling of well-being/malaise) orientated from the left (worst) to the right (best) The patient is invited to indicate a position (a point) along the line.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of NCGS in IBS subjects who responded to low FODMAPs diet</measure>
    <time_frame>3 weeks</time_frame>
    <description>To evaluate the NCGS, the response to the gluten challenge will be assessed by a visual analogue scale (VAS) before and after the dietary challenge. The VAS scale consists in is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptoms, pain, subjective feeling of well-being/malaise) orientated from the left (worst) to the right (best) The patient is invited to indicate a position (a point) along the line.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-celiac Gluten Sensitivity</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>patients with IBS treated with gluten</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving gluten</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with IBS treated with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>diet containing gluten</intervention_name>
    <description>gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days</description>
    <arm_group_label>patients with IBS treated with gluten</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet containing placebo</intervention_name>
    <description>Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days</description>
    <arm_group_label>patients with IBS treated with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a gluten-containing diet for at least six months before enrollment

          -  anti-transglutaminase antibodies (IgA and IgG) absence

          -  normal serum IgA levels

          -  prick and specific IgE tests for wheat allergy negative

        Exclusion Criteria:

          -  celiac disease

          -  wheat allergy

          -  chronic intestinal inflammatory diseases

          -  psychiatric disorders

          -  major abdominal surgery (in particular intestinal resections)

          -  diabetes mellitus

          -  previous anaphylactic episodes

          -  gluten-free diet in the previous six months

          -  pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Barone</last_name>
    <role>Study Director</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michele Barone</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Catassi C, Elli L, Bonaz B, Bouma G, Carroccio A, Castillejo G, Cellier C, Cristofori F, de Magistris L, Dolinsek J, Dieterich W, Francavilla R, Hadjivassiliou M, Holtmeier W, KÃ¶rner U, Leffler DA, Lundin KE, Mazzarella G, Mulder CJ, Pellegrini N, Rostami K, Sanders D, Skodje GI, Schuppan D, Ullrich R, Volta U, Williams M, Zevallos VF, Zopf Y, Fasano A. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria. Nutrients. 2015 Jun 18;7(6):4966-77. doi: 10.3390/nu7064966.</citation>
    <PMID>26096570</PMID>
  </results_reference>
  <results_reference>
    <citation>Catassi C, Alaedini A, Bojarski C, Bonaz B, Bouma G, Carroccio A, Castillejo G, De Magistris L, Dieterich W, Di Liberto D, Elli L, Fasano A, Hadjivassiliou M, Kurien M, Lionetti E, Mulder CJ, Rostami K, Sapone A, Scherf K, Schuppan D, Trott N, Volta U, Zevallos V, Zopf Y, Sanders DS. The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients. 2017 Nov 21;9(11). pii: E1268. doi: 10.3390/nu9111268. Review.</citation>
    <PMID>29160841</PMID>
  </results_reference>
  <results_reference>
    <citation>Van den Houte K, Carbone F, Pannemans J, Corsetti M, Fischler B, Piessevaux H, Tack J. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterol J. 2019 Mar;7(2):307-315. doi: 10.1177/2050640618821804. Epub 2018 Dec 22.</citation>
    <PMID>31080615</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones AL. The Gluten-Free Diet: Fad or Necessity? Diabetes Spectr. 2017 May;30(2):118-123. doi: 10.2337/ds16-0022.</citation>
    <PMID>28588378</PMID>
  </results_reference>
  <results_reference>
    <citation>Calasso M, Francavilla R, Cristofori F, De Angelis M, Gobbetti M. New Protocol for Production of Reduced-Gluten Wheat Bread and Pasta and Clinical Effect in Patients with Irritable Bowel Syndrome: A randomised, Double-Blind, Cross-Over Study. Nutrients. 2018 Dec 2;10(12). pii: E1873. doi: 10.3390/nu10121873.</citation>
    <PMID>30513824</PMID>
  </results_reference>
  <results_reference>
    <citation>Junker Y, Zeissig S, Kim SJ, Barisani D, Wieser H, Leffler DA, Zevallos V, Libermann TA, Dillon S, Freitag TL, Kelly CP, Schuppan D. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med. 2012 Dec 17;209(13):2395-408. doi: 10.1084/jem.20102660. Epub 2012 Dec 3.</citation>
    <PMID>23209313</PMID>
  </results_reference>
  <results_reference>
    <citation>Carroccio A, Rini G, Mansueto P. Non-celiac wheat sensitivity is a more appropriate label than non-celiac gluten sensitivity. Gastroenterology. 2014 Jan;146(1):320-1. doi: 10.1053/j.gastro.2013.08.061. Epub 2013 Nov 22.</citation>
    <PMID>24275240</PMID>
  </results_reference>
  <results_reference>
    <citation>Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19. pii: S0016-5085(16)00223-7. doi: 10.1053/j.gastro.2016.02.032. [Epub ahead of print]</citation>
    <PMID>27144617</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Michele Barone</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gluten free diet</keyword>
  <keyword>FODMAPs</keyword>
  <keyword>gastrointestinal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

